← Markets

Corvus Pharmaceuticals, Inc.

CRVS · NASDAQ

Market closed$14.90$0.630000 (+4.41%)After hours $15.00 · +0.67%

Key statistics

Previous close$14.27
Open$14.24
Day high$15.20
Day low$13.90
52-week high$26.95
52-week low$3.96
Market cap1.25B
Volume773.27K
Average volume1.57M
P/E ratio-28.65
Forward P/E—
EPS-0.52
Dividend yield0.00%

Market context

Why it moved

Corvus Pharmaceuticals (CRVS) shares surged on heightened investor interest and strong momentum in the biotech sector, with the stock posting notable gains amid active trading volume that reflects renewed market enthusiasm for the clinical-stage oncology company.

StockinvestStocktwitsYelpPedalcommanderPaybis

What is happening

Recent company-specific developments and publisher coverage.

July 18, 2026Corvus Pharmaceuticals gained over 4% as the broader healthcare sector found support amid positive earnings from peers like Abbott Laboratories and UnitedHealth, with UBS upgrading its sector outlook on improving fundamentals and biotech M&A tailwinds. The move builds on sustained momentum since Goldman Sachs initiated coverage in April with a Buy rating and $40 price target, citing Soquelitinib's compelling early Phase 2 data in atopic dermatitis, with 75% of patients achieving EASI-75 response — positioning Corvus as a leading oral contender in the large post-Dupixent market.

4.4149

July 17, 2026Corvus Pharmaceuticals declined sharply, with shares falling over 4% during the session and continuing lower in after-hours trading, significantly underperforming the broader healthcare sector (XLV) and the S&P 500. The selloff comes amid a mixed tape for biotech, with AI-linked and chip stocks dragging markets lower on July 16. While no fresh CRVS-specific catalyst was identified today, the stock remains in focus following Goldman Sachs' April initiation at Buy with a $40 price target, citing Soquelitinib's compelling early Phase 2 data in atopic dermatitis — where 75% of patients achieved at least a 75% eczema improvement. Investors continue to weigh the company's clinical progress against broader biotech sector headwinds.

-4.3566

July 14, 2026Corvus Pharmaceuticals edged higher in regular trading, gaining nearly 2%, before slipping in after-hours as investors navigate a volatile backdrop for small-cap biotech. The broader healthcare sector faced headwinds ahead of major earnings from J&J, UnitedHealth, and Abbott—collectively representing over 20% of XLV—while a cooler-than-expected June CPI print (3.5%) helped lift equities during the session. Biotech broadly faces a projected 79% earnings drop for Q2, keeping sentiment cautious for clinical-stage names like Corvus even as macro relief provided some intraday support.

1.7675

July 10, 2026Corvus Pharmaceuticals closed down roughly 3% as shares gave back ground despite a broadly positive biotech backdrop — Jim Cramer recently called biotech "the hottest group in the market," and the healthcare sector has risen nearly 9.5% last quarter. The pullback comes after a strong run fueled by Goldman Sachs' April initiation at Buy with a $40 price target, citing Soquelitinib's promising Phase 2 data in atopic dermatitis (75% of patients achieved ≥75% eczema improvement). With XLV holding near flat in after-hours, CRVS's decline appears stock-specific rather than sector-driven.

-3.2716

July 9, 2026Corvus Pharmaceuticals shares rose nearly 3% in a broadly challenged market, outperforming the healthcare sector (XLV) as biotech continues to benefit from a notable rotation out of crowded semiconductor and AI hardware names. The backdrop is favorable: Jim Cramer recently called biotech 'the hottest group in the market,' citing a more permissive FDA environment and an expected wave of M&A deals, while Goldman Sachs' April Buy initiation with a $40 price target — citing Soquelitinib's strong early atopic dermatitis data and an undervalued oral therapy platform — continues to underpin bullish sentiment. Volume came in well above average, suggesting active investor interest even as broader markets faced headwinds from escalating U.S.-Iran tensions and rising oil prices.

2.8791

June 30, 2026Corvus Pharmaceuticals surged over 7% as investors continued to build positions in the clinical-stage biotech ahead of Phase 2 trial catalysts for soquelitinib, its oral atopic dermatitis therapy. The move came amid a broader market rebound driven by a U.S.-Iran ceasefire agreement that snapped a five-day losing streak for the S&P 500, while healthcare remained a standout sector — with XLV closing near its 52-week high. Goldman Sachs' April 'Buy' initiation with a $40 price target citing a 'leading emerging' oral option in the post-Dupixent AD market continues to underpin bullish sentiment, with consensus targets around $33 implying significant upside from current levels.

7.3388

June 27, 2026Corvus Pharmaceuticals gained amid a strong rotation into healthcare, with the sector posting its best weekly performance since June 2022 and closing as the top-performing sector on the day. The advance builds on persistent investor interest in the company's lead asset, soquelitinib, an oral ITK inhibitor being evaluated for atopic dermatitis, peripheral T-cell lymphoma, and other indications, with Phase 3 PTCL data expected late 2026. Goldman Sachs' April 'Buy' initiation with a $40 price target continues to underpin sentiment, even as some analysts flag valuation concerns at current levels.

3.3716

June 24, 2026Corvus Pharmaceuticals gained 2.53% amid a healthcare sector that led early market gains on Tuesday, offering a contrast to the broader tech-driven volatility that rattled global markets. A key catalyst for investor attention is a June 11 insider purchase of 21,700 shares by a company director — a signal of internal confidence as the company advances soquelitinib, its selective ITK inhibitor, toward a pivotal Phase 3 PTCL data readout expected in late 2026. The broader biotech sector has shown resilience in 1H 2026, and M&A speculation around immunology assets — highlighted by AbbVie's reported ~$11B pursuit of Apogee Therapeutics — adds a tailwind to sentiment around CRVS.

2.5337

Pharma Voice · June 16, 2026Corvus CEO thinks his next blockbuster is an ITK inhibitorSimply Wall Street · June 15, 2026Corvus Pharmaceuticals (CRVS) Is Up 7.3% After Promising Soquelitinib Data And Extended Cash RunwayStock Titan · June 9, 2026$13.5M bet on soquelitinib: China eczema and asthma trials move aheadSeeking Alpha · May 19, 2026Corvus Pharmaceuticals: The Market Is Pricing Atopic Dermatitis Success Too Early (CRVS)Simply Wall Street · May 10, 2026Is It Too Late To Consider Corvus Pharmaceuticals (CRVS) After A 335% One Year Surge?Stocktwits · April 17, 2026CRVS Stock Surges 10%, Hits 50-DMA For First Time In A Month – Here’s Why Goldman Sachs Sees A 166% UpsideInvesting.com · April 17, 2026Goldman Sachs initiates Corvus Pharmaceuticals stock with buy ratingTradingView · January 20, 2026What made Corvus stock double on Tuesday and is it sustainable?
Benzinga · June 9, 2026Corvus Pharma Participates In New $13.5M Financing For Angel Pharmaceuticals
Benzinga · April 17, 2026Watching Corvus Pharmaceuticals; CNBC Reports "This biopharma stock could more than double on oral eczema treatment, Goldman Sachs says"
Benzinga · April 17, 2026Goldman Sachs Initiates Coverage On Corvus Pharmaceuticals with Buy Rating, Announces Price Target of $40
Mt Newswire · April 17, 2026Goldman Sachs Initiates Corvus Pharmaceuticals at Buy With $40 Price Target
Mt Newswire · March 13, 2026Oppenheimer Adjusts Price Target on Corvus Pharmaceuticals to $33 From $32, Maintains Outperform Rating
Mt Newswire · March 12, 2026Corvus Pharmaceuticals Q4 Loss Narrows
Mt Newswire · March 12, 2026Earnings Flash (CRVS) Corvus Pharmaceuticals Posts Q4 Loss $-0.15, vs. FactSet Est of Loss of $-0.13
Benzinga · March 12, 2026Corvus Pharma Q4 EPS $(0.15) Misses $(0.13) Estimate

Peers

S&P 500SPX · $7,457.69-1.01%Arcus Biosciences, Inc.RCUS · $27.37+2.74%Tango Therapeutics, Inc.TNGX · $28.56+3.33%Monte Rosa Therapeutics, Inc.GLUE · $24.56+6.04%Gossamer Bio, Inc.GOSS · $0.170100-0.23%Vanda Pharmaceuticals Inc.VNDA · $5.44-0.18%Dianthus Therapeutics, Inc.DNTH · $105.60+10.75%Oruka Therapeutics, Inc.ORKA · $92.70+11.63%Prothena Corporation plcPRTA · $8.66+2.24%Replimune Group, Inc.REPL · $10.23+7.46%Alumis Inc.ALMS · $28.66+5.25%ORIC Pharmaceuticals, Inc.ORIC · $10.730.00%